DiaMedica Therapeutics Inc DMAC
News
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences